Undervalued and Insider Buying at Riley Financial

 The Fool has noted that Riley Financial CEO has been buying shares over the past year.  Many metrics also show that this company is still undervalued despite its recent run up. 

Small Article on Schrodinger

 The Fool has a small article on Schrodinger and why it is one of their highest conviction picks.  The author also notes that OptimizeRX is another one of his high conviction picks. 

On Avinger

 

This medical devices company could be a takeover candidate. Avinger Inc. (NASDAQ: AVGR) designs, manufactures and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. Its lumivascular platform integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

In addition, its first-generation chronic total occlusion-crossing catheters, Wildcat and Kittycat 2, employ a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across such an occlusion.

B. Riley Securities has started coverage with a $2.50 price target, which is right in line with the consensus target.

More on Chewy

 The Fool makes a good case for investing in Chewy. 

On StoneCO

 The Fool owns shares of StoneCO.  Some developments in the stock this week:

1. On June 16, 2021, the Brazilian Antitrust Authority approved the business combination between Stone and Linx. Linx is a leading provider of retail management software in Brazil, which will provide Stone's solutions to Brazilian merchants. 
2. StoneCo has strong fundamentals when you look at its TTM. The company has profitable earnings and more cash and short-term investment than debt.

Vertex Pharma

 Vertex pharma is a rare blend of growth and value according to this article at the Fool. 

UI Path

 UIPath recently had its IPO at $56.  This stock could be the market leader in robot automation.  Kathy Wood also bought shares recently. 

$10 Price Target on Daseke

 According to this article, there is a $10 price target on Daseke. 

Absolute Software

 The Fool has a short article on Absolute Software, a small cap IT Security company that also pays a dividend.

On Exact Sciences

 The Fool and Cathy Wood both believe in Exact Sciences, but the company is not profitable and the stock is not cheap.